Apogee Therapeutics Management
Management criteria checks 1/4
Apogee Therapeutics' CEO is Michael Henderson, appointed in Sep 2022, has a tenure of 3.58 years. total yearly compensation is $13.21M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $97.18M. The average tenure of the management team and the board of directors is 3.3 years and 2.8 years respectively.
Key information
Michael Henderson
Chief executive officer
US$13.2m
Total compensation
| CEO salary percentage | 5.01% |
| CEO tenure | 3.6yrs |
| CEO ownership | 1.4% |
| Management average tenure | 3.3yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Apogee Therapeutics: Two Shots A Year, One Shot At Disruption
Mar 23Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
May 30
Apogee Therapeutics: Engineering Biologic Dominance
Apr 14Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Nov 10Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$256m |
| Sep 30 2025 | n/a | n/a | -US$254m |
| Jun 30 2025 | n/a | n/a | -US$238m |
| Mar 31 2025 | n/a | n/a | -US$205m |
| Dec 31 2024 | US$13m | US$662k | -US$182m |
| Sep 30 2024 | n/a | n/a | -US$147m |
| Jun 30 2024 | n/a | n/a | -US$118m |
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$9m | US$565k | -US$84m |
| Sep 30 2023 | n/a | n/a | -US$70m |
| Jun 30 2023 | n/a | n/a | -US$69m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$6m | US$146k | -US$43m |
Compensation vs Market: Michael's total compensation ($USD13.21M) is above average for companies of similar size in the US market ($USD8.37M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Henderson (35 yo)
Dr. Michael Thomas Henderson, M.D. serves as Chief Executive Officer at Apogee Therapeutics, Inc. since September 2022 and Director since June 2023. He had been Chief Business Officer of BridgeBio Pharma,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.6yrs | US$13.21m | 1.43% $ 97.2m | |
| Chief Financial Officer | 3.3yrs | US$5.08m | 0.24% $ 16.4m | |
| Chief Medical Officer | 3.6yrs | US$5.08m | 0.21% $ 14.2m | |
| Vice President of Investor Relations | 2.8yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 2.7yrs | no data | no data | |
| SVP & Head of People | 3.4yrs | no data | no data | |
| Chief Development Officer | 2yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 3.3yrs | no data | no data | |
| Senior VP and Head of Regulatory Affairs & Toxicology | 3.5yrs | no data | no data | |
| Senior Vice President of Finance | 2.9yrs | no data | no data | |
| Senior Vice President of Program & Portfolio | no data | no data | no data | |
| Chief Business Officer | no data | no data | no data |
Experienced Management: APGE's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$13.21m | 1.43% $ 97.2m | |
| Independent Director | 2.8yrs | US$409.83k | 0.022% $ 1.5m | |
| Independent Director | 2.8yrs | US$402.83k | 0.022% $ 1.5m | |
| Independent Director | 2.8yrs | US$393.83k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$389.83k | 0.069% $ 4.7m | |
| Independent Chairman of the Board | 2.7yrs | US$4.11m | 0.027% $ 1.8m | |
| Independent Director | 2.8yrs | US$397.33k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$398.11k | 0.069% $ 4.7m | |
| Independent Director | 1.9yrs | US$999.45k | 0% $ 0 |
Experienced Board: APGE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 18:58 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apogee Therapeutics, Inc. is covered by 19 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Julian Harrison | BTIG |
| Edward Nash | Canaccord Genuity |